HIVHITIDES-H3NCT05901272
Implementation of Collaborative Care for Depression in VA HIV Clinics
A study testing Local clinical champion, Learning collaborative and External facilitation in people with HIV and Depression, run by VA Office of Research and Development at 1 site in United States.
Trial summary
HIV Translating Initiatives for Depression into Effective Solutions (HITIDES) is a team-based service to manage depression in Veterans Living with HIV (VLWH). This service is more effective for managing depression than the care VLWH usually receive and saves resources. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- HIV, Depression
- What is being tested?
- Local clinical champion, Learning collaborative and External facilitation
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 8 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Aug 2024to 31 Jul 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- The research team will work with VISN 10 to identify sites that
- have an adequately sized (i.e. greater than 20) population of Veterans Living with HIV,
- have adequate PHQ-2 screen data to assess depression prevalence,
- can identify a clinical champion for implementation activities,
- are willing to participate, and
- allow for diversity and balance of clinic characteristics across arms (e.g. rate of referral to specialty mental health for VLWH and presence of HIV-only specialty clinic versus broad infectious disease clinic).
- For criterion 5, these factors that are important will be determined with VISN 10 clinical leadership and the research advisory council. Randomization at the VAMC level has limited ability to completely balance observed and unobserved health-system factors. However, efforts to balance key site characteristics are important; therefore, site-level characteristics thought to impact implementation efforts were identified by building consensus among HIV, Hepatitis, and Related Conditions Program (HHRC) leadership and the HIV care and implementation experts on the research team. Data on the following observable site-level characteristics will be collected from these sites during Year 1 of the study: baseline PHQ-2 screen rate, clinic size (unique patients, provider full-time equivalents [FTE], change in enrollment over the past 3 years), and current care manager FTE. Based on the five criteria described above and the power calculation below, eight eligible sites will be selected. Sites will be grouped into four couplets based on balance of the identified site-level characteristics.
Who cannot join
- -None.
Trial locations and contacts
1 site in 1 country.
United States1 site
Central Arkansas Veterans Healthcare System , Little Rock, AR
Little Rock, Arkansas, 72205
About this study
Official title: Implementation of Collaborative Care for Depression in VA HIV Clinics: Translating Initiatives for Depression Into Effective Solutions (HITIDES)
HIV Translating Initiatives for Depression into Effective Solutions (HITIDES) is a team-based service to manage depression in Veterans Living with HIV (VLWH). This service is more effective for managing depression than the care VLWH usually receive and saves resources. HITIDES is also liked by HIV care providers and VLWH. Despite this, no VA clinics currently offer this service. This study examines two approaches to engage clinics with HITIDES, the resulting effects on VLWH, and the costs of these approaches. The first approach includes recruiting an HIV care provider at the site to help connect with the service and a network of providers to support this person. The second approach uses an additional external expert to facilitate these connections. Understanding how to connect Veterans to the HITIDES service will allow VA to improve depression care for VLWH and save VA resources.
Read the detailed description
Background: HIV Translating Initiatives for Depression into Effective Solutions (HITIDES) is a collaborative care intervention that adapts the primary care collaborative care model for depression treatment to HIV clinics. In a randomized controlled trial, HITIDES significantly improved depression symptoms for Veterans Living with HIV (VLWH) and delivered cost savings. However, no VHA HIV clinics have implemented HITIDES. The goal of this study is to support broad implementation of the HITIDES intervention by testing two appropriate implementation strategies: a clinical champion from each site who, with the help of a learning collaborative of peers, will work with local clinicians and leadership to implement the HITIDES intervention at their site with and without the assistance of external facilitation from an implementation expert.
Significance/Impact: Preliminary work has been completed to identify implementation strategies acceptable to VLWH and HIV care providers; however, the relative effectiveness and cost of these implementation strategies is unknown. While the HITIDES depression care team (DCT) is housed off-site and can deliver services consistently with high quality and fidelity, the ability of the DCT to interface and engage with HIV care providers at sites is unknown. Additionally, the mediating effect of site-level implementation outcomes such as reach and adoption on effectiveness of the intervention is unknown. Because the DCT can provide services to multiple HIV clinics, a small-scale rollout of the intervention is needed before considering a national roll out.
Innovation: This study employs an innovative hybrid study design to concurrently examine implementation and effectiveness outcomes. The use of implementation success as a mediating factor for intervention effectiveness is also novel. The relative ability of implementation activities to impact care for vulnerable populations is an area of research where little is known. VHA HIV clinics are an ideal test case for examining these questions because VLWH are a group where racial minority, low income, sexual minority Veterans are disproportionately represented.
Specific Aims: 1) Determine, through a cluster-randomized controlled trial among VHA HIV clinics, the effect of adding external facilitation to an implementation strategy consisting of a site-level clinical champion and learning collaborative. 2) Determine the impact of HITIDES on changes in depression and suicidal ideation among HIV-positive Veterans receiving the intervention. 3) Estimate the budget impact of HITIDES implementation strategies by calculating the costs of each strategy.
Methodology: The use of a hybrid type-3 effectiveness-implementation trial to examine the interaction of implementation and intervention effectiveness is an innovative methodology ideal for situations where the lack of robust evidence of effectiveness is coupled with a cost-saving intervention. This hybrid trial will use a cluster randomization of 8 VHA HIV clinics. These clinics will be chosen for balance and diversity of clinic characteristics and randomly assigned to one of the two implementation arms. Evaluation of each aim will use a mix of primary (e.g., QUERI-developed time-tracking tool) and secondary (e.g., clinical data warehouse) data. The investigators expect the clinical champion, learning collaborative, and external facilitation arm to be associated with greater reach and adoption; however, the clinical champion and learning collaborative alone arm is expected to be less costly.
Next steps: The findings from implementation of the HITIDES intervention to 8 VHA HIV clinics will be used to inform selection of implementation strategies for a broad roll out in the future. Findings will be presented in cooperation with the investigators operational partner, VA HIV, Hepatitis C, and Related Condition Program to VACO and VISN leadership.
- Conditions
- HIV, Depression
- Being tested
- Local clinical champion, Learning collaborative, External facilitation
- Keywords
- HIV, Depression, Hybrid type 3 effectiveness-implementation trial, Facilitation
- Medical subject headings
- Depression
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Local clinical championOther
A clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC.
Learning collaborativeOther
Learning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation.
External facilitationOther
. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships.
| Study group | Role | What they receive |
|---|---|---|
| Implementation strategy bundle 1 | Other | Local clinical champion and learning collaborative. Receives: Other: Local clinical champion; Other: Learning collaborative |
| Implementation strategy bundle 2 | Other | Local clinical champion, learning collaborative, and external facilitation. Receives: Other: Local clinical champion; Other: Learning collaborative; Other: External facilitation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reach
Reach. Reach will be calculated as a proportion of eligible patients receiving the intervention at 12 months. The primary comparison of interest, and the one on which the study is powered, is the comparison of reach at 12 months in Arm 1 vs. Arm 2.
Measured: 12 months
Secondary outcomes (7)
Reach
Reach. Reach will be calculated as a proportion of eligible patients receiving the intervention at 18 months.
Measured: 18 months
Adoption
Adoption will be assessed at 12 months. The investigators will calculate a proportion of providers adopting intervention recommendations.
Measured: 12 months
Depression - Patient Health Questionnaire-9
The PHQ-9 is the depression module of the PHQ and has high sensitivity and specificity for a major depression diagnosis. Additionally, the PHQ-9, which has a score range of 0 to 27, provides a reliable estimate of depression severity. Scores of 5, 10, 15, and 20 correspond to mild, moderate, moderately severe, and severe depression, respectively. Each of the nine items of the instrument has choices ranging from "0=Not at all" and "3=Nearly every day." These choices apply to the question, "Over the past two weeks, how often have you been bothered by the following problems?" The list of problems includes common depressive symptoms such as "Little interest or pleasure in doing things." The DCM will conduct the PHQ-9 at baseline (PHQ-9 of at least 10 required to continue intervention) and at the 12 month follow-up call for HITIDES patients.
Measured: 12 months
Suicidal ideation - Columbia-Suicide Severity Rating Scale
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a valid and reliable measure of suicidal ideation that is sensitive and specific to identifying suicidal ideation and predictive of suicide attempts. (Posner, Brent, Lucas, \& al., 2010) Moreover, the C-SSRS ideation and behavioral subscales are both sensitive to change over time. (Posner, Brown, Stanley, \& al., 2011). The investigators will consider suicidal ideation reduction as a decrease of one or more in the C-SSRS score and suicidal ideation remission as a move from any nonzero score to zero. Veterans are asked 3 to 6 questions, depending on whether suicidal ideation is endorsed. The current VHA process for comprehensive suicide risk assessment is for providers to administer the PHQ-2 plus the PHQ suicidal ideation question, which, if positive, prompts the administration of C-SSRS. The investigators will code Veterans as not having suicidal ideation if the C-SSRS score equals 0.
Measured: 12 months
Cost - Budget Impact
The base-case analysis estimates the difference in illness costs before and after the intervention's implementation plus the cost of implementation. Marginal effects (ME) will be calculated for outpatient and pharmacy utilization and cost. Additionally, MEs will be calculated for each outpatient encounter and medication type. To estimate MEs between the implementation arms, the investigators will calculate two predicted values for each patient based on regression of case-mix variables at the site level. Only covariates found to predict dependent variables at the p<0.10 level in a bivariate analysis will be included in the regression. By calculating the difference between the predictions, the effect of the intervention on an individual patient can be estimated. Averaging this value gives an average ME for the intervention.
Measured: 12 months
Adoption
Adoption will be assessed at 18 months. The investigators will calculate a proportion of providers adopting intervention recommendations.
Measured: 18 months
Depression - Patient Health Questionnaire-9
The PHQ-9 is the depression module of the PHQ and has high sensitivity and specificity for a major depression diagnosis. Additionally, the PHQ-9, which has a score range of 0 to 27, provides a reliable estimate of depression severity. Scores of 5, 10, 15, and 20 correspond to mild, moderate, moderately severe, and severe depression, respectively. Each of the nine items of the instrument has choices ranging from "0=Not at all" and "3=Nearly every day." These choices apply to the question, "Over the past two weeks, how often have you been bothered by the following problems?" The list of problems includes common depressive symptoms such as "Little interest or pleasure in doing things." The DCM will conduct the PHQ-9 at baseline (PHQ-9 of at least 10 required to continue intervention) and at the 18 month follow-up call for HITIDES patients.
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jun 2023
- Study start1 Aug 2024
- Primary completion31 Jul 2026 (estimated)
- Study completion31 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for HIVStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This is a two-arm randomized controlled trial (RCT) with four VA HIV clinics in each arm. Arm 1 receives a learning collaborative and clinical champions at each site Arm 2 receives these plus external facilitation. Learning collaboratives will be hosted separately for sites in Arm 1 and sites in Arm 2 to avoid contamination. Across all aims, there are research activities proposed to evaluate the quality improvement (referred to as "implementation strategy bundles"). All implementation strategy bundles are supported by educational materials about HITIDES and tools to engage Veterans in implementation activities.
- Masking
- None (open label)
- Enrolment
- 8 participants (actual)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Jacob T Painter, PhD PharmD, Principal investigator, Central Arkansas Veterans Healthcare System , Little Rock, AREva N Woodward, PhD MA BS, Principal investigator, Central Arkansas Veterans Healthcare System , Little Rock, AR
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05901272
- Sponsor's protocol ID
- IIR 18-294
- Other IDs
- I01HX002759-01A1
- Acronym
- HITIDES-H3
- Status last verified
- Jul 2026
- First submitted
- 10 May 2023
- Last updated
- 21 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Painter JT, Pyne J, Curran G, Raciborski RA, Russell S, Fortney J, Gifford AL, Ohl M, Woodward EN. Implementation of collaborative care for depression in VA HIV clinics: Translating Initiatives for Depression into Effective Solutions (HITIDES): protocol for a cluster-randomized type 3 hybrid effectiveness-implementation trial. Implement Sci Commun. 2024 Sep 16;5(1):99. doi: 10.1186/s43058-024-00639-z.
PubMed 39285308
Study at a glance
From the registry record, last updated by the sponsor on 21 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation of Collaborative Care for Depression in VA HIV Clinics: Translating Initiatives for Depression Into Effective Solutions (HITIDES)
- ClinicalTrials.gov ID
- NCT05901272
- Acronym / sponsor ID
- HITIDES-H3 / IIR 18-294
- Conditions
- HIV, Depression
- Keywords
- HIV, Depression, Hybrid type 3 effectiveness-implementation trial, Facilitation
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 8 participants (actual)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Study start
- 1 Aug 2024 (actual)
- Primary completion
- 31 Jul 2026 (estimated)
- Study completion
- 31 Jul 2027 (estimated)
- First posted
- 13 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
HIV Translating Initiatives for Depression into Effective Solutions (HITIDES) is a team-based service to manage depression in Veterans Living with HIV (VLWH). This service is more effective for managing depression than the care VLWH usually receive and saves resources. HITIDES is also liked by HIV care providers and VLWH. Despite this, no VA clinics currently offer this service. This study examines two approaches to engage clinics with HITIDES, the resulting effects on VLWH, and the costs of these approaches. The first approach includes recruiting an HIV care provider at the site to help connect with the service and a network of providers to support this person. The second approach uses an additional external expert to facilitate these connections. Understanding how to connect Veterans to the HITIDES service will allow VA to improve depression care for VLWH and save VA resources.
Detailed description
Background: HIV Translating Initiatives for Depression into Effective Solutions (HITIDES) is a collaborative care intervention that adapts the primary care collaborative care model for depression treatment to HIV clinics. In a randomized controlled trial, HITIDES significantly improved depression symptoms for Veterans Living with HIV (VLWH) and delivered cost savings. However, no VHA HIV clinics have implemented HITIDES. The goal of this study is to support broad implementation of the HITIDES intervention by testing two appropriate implementation strategies: a clinical champion from each site who, with the help of a learning collaborative of peers, will work with local clinicians and leadership to implement the HITIDES intervention at their site with and without the assistance of external facilitation from an implementation expert.
Significance/Impact: Preliminary work has been completed to identify implementation strategies acceptable to VLWH and HIV care providers; however, the relative effectiveness and cost of these implementation strategies is unknown. While the HITIDES depression care team (DCT) is housed off-site and can deliver services consistently with high quality and fidelity, the ability of the DCT to interface and engage with HIV care providers at sites is unknown. Additionally, the mediating effect of site-level implementation outcomes such as reach and adoption on effectiveness of the intervention is unknown. Because the DCT can provide services to multiple HIV clinics, a small-scale rollout of the intervention is needed before considering a national roll out.
Innovation: This study employs an innovative hybrid study design to concurrently examine implementation and effectiveness outcomes. The use of implementation success as a mediating factor for intervention effectiveness is also novel. The relative ability of implementation activities to impact care for vulnerable populations is an area of research where little is known. VHA HIV clinics are an ideal test case for examining these questions because VLWH are a group where racial minority, low income, sexual minority Veterans are disproportionately represented.
Specific Aims: 1) Determine, through a cluster-randomized controlled trial among VHA HIV clinics, the effect of adding external facilitation to an implementation strategy consisting of a site-level clinical champion and learning collaborative. 2) Determine the impact of HITIDES on changes in depression and suicidal ideation among HIV-positive Veterans receiving the intervention. 3) Estimate the budget impact of HITIDES implementation strategies by calculating the costs of each strategy.
Methodology: The use of a hybrid type-3 effectiveness-implementation trial to examine the interaction of implementation and intervention effectiveness is an innovative methodology ideal for situations where the lack of robust evidence of effectiveness is coupled with a cost-saving intervention. This hybrid trial will use a cluster randomization of 8 VHA HIV clinics. These clinics will be chosen for balance and diversity of clinic characteristics and randomly assigned to one of the two implementation arms. Evaluation of each aim will use a mix of primary (e.g., QUERI-developed time-tracking tool) and secondary (e.g., clinical data warehouse) data. The investigators expect the clinical champion, learning collaborative, and external facilitation arm to be associated with greater reach and adoption; however, the clinical champion and learning collaborative alone arm is expected to be less costly.
Next steps: The findings from implementation of the HITIDES intervention to 8 VHA HIV clinics will be used to inform selection of implementation strategies for a broad roll out in the future. Findings will be presented in cooperation with the investigators operational partner, VA HIV, Hepatitis C, and Related Condition Program to VACO and VISN leadership.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- This is a two-arm randomized controlled trial (RCT) with four VA HIV clinics in each arm. Arm 1 receives a learning collaborative and clinical champions at each site Arm 2 receives these plus external facilitation. Learning collaboratives will be hosted separately for sites in Arm 1 and sites in Arm 2 to avoid contamination. Across all aims, there are research activities proposed to evaluate the quality improvement (referred to as "implementation strategy bundles"). All implementation strategy bundles are supported by educational materials about HITIDES and tools to engage Veterans in implementation activities.
| Arm | Type | Receives |
|---|---|---|
| Implementation strategy bundle 1 | Other | Other: Local clinical champion, Other: Learning collaborativeLocal clinical champion and learning collaborative. |
| Implementation strategy bundle 2 | Other | Other: Local clinical champion, Other: Learning collaborative, Other: External facilitationLocal clinical champion, learning collaborative, and external facilitation. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (7 listed)
- The research team will work with VISN 10 to identify sites that
- have an adequately sized (i.e. greater than 20) population of Veterans Living with HIV,
- have adequate PHQ-2 screen data to assess depression prevalence,
- can identify a clinical champion for implementation activities,
- are willing to participate, and
Key exclusion criteria (1 listed)
- -None.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Local clinical championA clinical champion is a local provider who serves as a liaison between local clinics and local or regional leadership or national program offices (e.g., HHRC) and advocates for the HITIDES intervention with their local peers. A clinical champion can provide ongoing promotion of and education about HITIDES and remind care providers of its presence and value either formally (e.g., presentations at staff meetings) or informally (e.g., individual conversations about HITIDES benefits). Clinical champions can also engage middle managers or local leadership to buy in to and support intervention uptake. Clinical champions may also work with Veterans in quality improvement efforts to garner their ideas for how to outreach to other Veteran patients, plan quality improvement cycles, or consult in an advisory capacity. Potential champions will be approached about participation after consultation with site HIV care providers and HHRC. | Other | Implementation strategy bundle 1, Implementation strategy bundle 2 |
| Learning collaborativeLearning Collaboratives are groups of providers or provider organizations and foster a collaborative learning environment to improve implementation of the clinical innovation (HITIDES). There are several approaches to this in the literature including peer consultation networks, online communities of practice, quality circles, and learning collaboratives. Groups will meet virtually using a wide variety of media. Participation will be monitored by research staff and recorded by participants in a time-tracking log but not controlled. The learning collaboratives will be comprised of a group of site clinical champions, HIV care providers, and other VHA HIV care representatives, potentially including Veterans who are engaged in implementation activities, to foster a learning environment to improve the implementation of HITIDES through consultation. | Other | Implementation strategy bundle 1, Implementation strategy bundle 2 |
| External facilitation. External facilitation will be provided by a trained external facilitator who is given the HITIDES Operations Guide and Consumer Voice tools for Veteran engagement in quality improvement. Facilitation is a process to enable sites to increase uptake of HITIDES through supportive relationships and strategies to navigate the implementation process. Virtual external facilitation is a recognized modality of facilitation delivery in VHA. The external facilitator will work with the clinical champion, site personnel, and Veterans-not conducting research activities but engaging in quality improvement processes with these individuals. The addition of a facilitator allows problem identification and problem-solving, using processes based on supportive relationships. | Other | Implementation strategy bundle 2 |
Primary outcome
Reach
Time frame: 12 months
Reach. Reach will be calculated as a proportion of eligible patients receiving the intervention at 12 months. The primary comparison of interest, and the one on which the study is powered, is the comparison of reach at 12 months in Arm 1 vs. Arm 2.
7 secondary outcomes
Reach
Time frame: 18 months
Adoption
Time frame: 12 months
Depression - Patient Health Questionnaire-9
Time frame: 12 months
Suicidal ideation - Columbia-Suicide Severity Rating Scale
Time frame: 12 months
Cost - Budget Impact
Time frame: 12 months
Adoption
Time frame: 18 months
Depression - Patient Health Questionnaire-9
Time frame: 18 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jul 2026.
- Background: PubMed 39285308Painter JT, Pyne J, Curran G, Raciborski RA, Russell S, Fortney J, Gifford AL, Ohl M, Woodward EN. Implementation of collaborative care for depression in VA HIV clinics: Translating Initiatives for Depression into Effective Solutions (HITIDES): protocol for a cluster-randomized type 3 hybrid effectiveness-implementation trial. Implement Sci Commun. 2024 Sep 16;5(1):99. doi: 10.1186/s43058-024-00639-z.
- Individual participant dataSharing planned: No
Related trials for HIV
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
Prescribe to Prevent HIV: A Hybrid Trial Helping Addiction Clinics Prevent HIV & Infections Through Safer Drug Use Support
People Who Use Opioids/People With Opioid Use Disorder (OUD)
Recruiting
Evaluating the Impact of Using the B-OK Bottles for HIV and ART Literacy in South Africa
HIV, HIV Treatment
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
RecruitingObservational study
Olfactory Function and Model-Based Behavior in People Living With HIV and SUD
HIV, Substance Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jacob T Painter, PhD PharmD principal investigator
Central Arkansas Veterans Healthcare System , Little Rock, AR
Eva N Woodward, PhD MA BS principal investigator
Central Arkansas Veterans Healthcare System , Little Rock, AR
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Local clinical champion, Learning collaborative and External facilitation in people with HIV and Depression, run by VA Office of Research and Development at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 21 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reach (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05901272, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jul 2026.